A carregar...
DR-05 TREATMENT AND PROGNOSIS AFTER BEVACIZUMAB FAILURE IN RECURRENT GLIOBLASTOMA: THE CLEVELAND CLINIC EXPERIENCE
BACKGROUND: Bevacizumab (BEV) is FDA approved for treatment of recurrent glioblastoma (rGBM). There are no good treatment options for rGBM after progression on BEV. Our aim is to identify the patterns of treatment after initial progression on BEV and to estimate the median progression free survival...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218044/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou252.5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|